Ra Medical has re-upped its registration for an upcoming initial public offering looking to bring in approximately $86.3 million, according to a recently posted SEC filing.
Ra Medical produces the Dabra atherectomy catheter laser designed to treat patients with peripheral artery disease. The system is designed to destroy arteriosclerotic blockages through the use of radiation ablation, which the company touts as having significant advantages over traditional balloon angioplasty systems.
The Carlsbad, Calif.-based company originally registered for the IPO in July, saying it plans to list on the New York Stock Exchange under the symbol “RMED,” according to the filing.
Piper Jaffray and Cantor Fitzgerald are acting as joint book runners for the offering, according to the newly posted filing.
The company has not yet released details on the IPO, but had initially planned to launch the offering in February this year.
DeviceTalks Minnesota's leadership track is designed to provide attendees with insights on topics such as:
Use code SAVE15 to save 15%!